A Study of Infusion Site Pain After Infusion of Excipients in Participants With Type 1 Diabetes Mellitus - Trial NCT05067270
Access comprehensive clinical trial information for NCT05067270 through Pure Global AI's free database. This Phase 1 trial is sponsored by Eli Lilly and Company and is currently Completed. The study focuses on Type 1 Diabetes Mellitus. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Eli Lilly and Company
Timeline & Enrollment
Phase 1
Oct 22, 2021
Dec 06, 2021
Primary Outcome
Visual Analog Scale (VAS) Pain Score
Summary
The main purpose of this study is to evaluate the effect of excipients sodium citrate and
 treprostinil without insulin on local infusion site pain in participants with type 1 diabetes
 mellitus (T1DM) on continuous subcutaneous insulin infusion (CSII). The study may last up to
 36 days including a screening period and 3 visits.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05067270
Non-Device Trial